✦ LIBER ✦

Removing oxaliplatin from FOLFOX feasible in colorectal cancer

Book ID: 120852147
Publisher: Adis International Limited (now part of Wolters Kluwer Health)
Year: 2006
Weight: 120 KB
Volume: &NA;
Category: Article
ISSN: 1173-8324
DOI: 10.2165/00128413-200615280-00028

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCN30 ECONOMIC EVALUATION OF FOLFOX4 VER

PCN30 ECONOMIC EVALUATION OF FOLFOX4 VERSUS FOLFOX7 WITH OXALIPLATIN STOP-AND-GO IN ADVANCED COLORECTAL CANCER PATIENTS

✍ P Tilleul; G Jasso Mosqueda; A Trancart; AC Joly; C Tournigand; F Maindrault-Goe 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 74 KB

Oxaliplatin In Operable Colorectal Cance

Oxaliplatin In Operable Colorectal Cancer

✍ Gérard Milano 📂 Article 📅 2005 🏛 Springer International Publishing AG 🌐 English ⚖ 43 KB

Oxaliplatin In Operable Colorectal Cance

Oxaliplatin In Operable Colorectal Cancer

✍ Jacques Wils 📂 Article 📅 2005 🏛 Springer International Publishing AG 🌐 English ⚖ 56 KB

Oxaliplatin/fluorouracil/leucovorin (FOL

Oxaliplatin/fluorouracil/leucovorin (FOLFOX4 and modified FOLFOX6) in patients with refractory or advanced colorectal cancer: post-approval Japanese population experience

✍ Toshio Shimizu; Taroh Satoh; Kenji Tamura; Tomohiro Ozaki; Isamu Okamoto; Masahi 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 259 KB

FOLFOX4: clear benefit in colorectal can

FOLFOX4: clear benefit in colorectal cancer

📂 Article 📅 2002 🏛 Adis International Limited (now part of Wolters Kl ⚖ 195 KB

Capecitabine plus oxaliplatin (XELOX) ve

Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer

✍ Michel Ducreux; Jaafar Bennouna; Mohamed Hebbar; Marc Ychou; Gérard Lledo; Thier 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 French ⚖ 440 KB

## Abstract A regimen consisting of 5‐fluorouracil/leucovorin plus oxaliplatin (FOLFOX‐6) is widely used in France in the first‐line treatment of metastatic colorectal cancer (MCRC). The aim of our study was to demonstrate the non‐inferiority of capecitabine plus oxaliplatin (XELOX) __versus__ FOLF